{
    "nctId": "NCT01073865",
    "briefTitle": "Study to Compare Zoladex\u2122 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer",
    "officialTitle": "An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX\u2122 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 222,
    "primaryOutcomeMeasure": "Number of Patients With Progression-free Survival (PFS) at 24 Weeks",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female \u226520 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 \u226510 pg/mL and FSH \u2264 30 mIU/mL within 4 weeks of randomisation.\n* Hormone sensitivity (ER positive) of primary or secondary tumour tissue.\n* Histological/cytological confirmation of breast cancer and are candidates to receive hormonal therapy as therapy for advanced breast cancer.\n\nExclusion Criteria:\n\n* Patients who have received tamoxifen or other hormonal therapies as adjuvant therapy for breast cancer within 24 weeks before randomisation and/or who have received prior treatment with hormonal therapies for advanced breast cancer\n* Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomisation\n* Patients who have relapsed during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy and/or",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}